Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma

Haematologica

Volumn 95, Issue 1, 2010, Pages 163-167

  Caers, Jo ^a,b   Hose, Dirk ^c,e   Kuipers, Ine ^a   Bos, Tomas Jan ^a   Van Valckenborgh, Els ^a   Menu, Eline ^a   De Bruyne, Elke ^a   Goldschmidt, Hartmut ^c,e   Van Camp, Ben ^a   Klein, Bernard ^d   Vanderkerken, Karin ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Nationales Centrum fur Tumorerkrankungen   (Germany)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Cellular proliferation; Multiple myeloma; Thymosin 4

Indexed keywords

THYMOSIN BETA4;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER INVASION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL RATE; THYMOSIN; TUMOR SUPPRESSOR PROTEINS;

EID: 73949121958     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.006411     Document Type: Article

References (26)

1. Goldstein AL, Badamchian M. Thymosins: chemistry and biological properties in health and disease. Expert Opin Biol Ther. 2004;4(4):559-73.
2. Hannappel E. beta-Thymosins. Ann NY Acad Sci. 2007;1112:21-37.
3. Chen C, Li M, Yang H, Chai H, Fisher W, Yao Q. Roles of thymosins in cancers and other organ systems. World J Surg. 2005; 29(3):264-70.
4. Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer. 2008;95(3):301-13.
5. Gondo H, Kudo J, White JW, Barr C, Selvanayagam P, Saunders GF. Differential expression of the human thymosin-beta 4 gene in lymphocytes, macrophages, and granulocytes. J Immunol. 1987;139(11): 3840-8.
6. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003;95 (22):1674-80.
7. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009;114(1): 128-43.
8. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD Jr, Barlogie B, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009;113(19):4614-26.
9. Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, Lewis J, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009;113(18):4331-40.
10. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118-27.
11. Radl J. Multiple myeloma and related disorders. Lessons from an animal model. Pathol Biol (Paris). 1999;47(2):109-14.
12. Manning LS, Berger JD, O'Donoghue HL, Sheridan GN, Claringbold PG, Turner JH. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer. 1992;66(6):1088-93.
13. Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, de Greef C, et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med. 2003;5(8):654-67.
14. Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol. 2004;172(4):2232-7.
15. Caers J, Menu E, De Raeve H, Lepage D, Van Valckenborgh E, Van Camp B, et al. Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. Br J Cancer. 2008;98 (12):1966-74.
16. Nummela P, Yin M, Kielosto M, Leaner V, Birrer MJ, Holtta E. Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts. Cancer Res. 2006;66(2):701-12.
17. Goldstein AL. Thymosin beta4: a new molecular target for antitumor strategies. J Natl Cancer Inst. 2003;95(22):1646-7.
18. Wang WS, Chen PM, Hsiao HL, Wang HS, Liang WY, Su Y. Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. Oncogene. 2004;23(39):6666-71.
19. Wang WS, Chen PM, Hsiao HL, Ju SY, Su Y. Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 colon cancer cells. Oncogene. 2003;22(21):3297-306.
20. Shimamura R, Kudo J, Kondo H, Dohmen K, Gondo H, Okamura S, et al. Expression of the thymosin beta 4 gene during differentiation of hematopoietic cells. Blood. 1990;76(5):977-84.
21. Spangelo BL, Pompilius M, Farrimond DD, Stevens N, Nieva R, Shroff S, et al. Presence of a peptide component of thymosin fraction-5 manifesting discrete cytostatic properties in HL-60 human promyelocytic leukemia cells. Int Immunopharmacol. 2005;5(7-8):1317-29.
22. Bonnet D, Lemoine FM, Frobert Y, Bonnet ML, Baillou C, Najman A, et al. Thymosin beta4, inhibitor for normal hematopoietic progenitor cells. Exp Hematol. 1996;24(7): 776-82.
23. Leeanansaksiri W, DeSimone SK, Huff T, Hannappel E, Huff TF. Thymosin beta 4 and its N-terminal tetrapeptide, AcSDKP, inhibit proliferation, and induce dysplastic, non-apoptotic nuclei and degranulation of mast cells. Chem Biodivers. 2004;1(7):1091-100.
24. Huang WQ, Wang BH, Wang QR. Thymosin beta4 and AcSDKP inhibit the proliferation of HL-60 cells and induce their differentiation and apoptosis. Cell Biol Int. 2006;30(6):514-20.
25. Menu E, Braet F, Timmers M, Van Riet I, Van Camp B, Vanderkerken K. The F-actin content of multiple myeloma cells as a measure of their migration. Ann NY Acad Sci. 2002;973:124-36.
26. Xu FL, Saunders WS. Actin and microtubules: working together to control spindle polarity. Cancer Cell. 2008;14(3):197-9.